Melanotan I Peptide Research – Complete Guide

Table of Contents

• Quick Facts
• What is Melanotan I?
• Molecular Structure and Core Properties
• Mechanisms of Action Being Investigated
• Major Areas of Research
• Pharmacokinetics and Biological Distribution
• Research Limitations and Evidence Gaps
• Regulatory and Research Status
• Key Research Findings
• Frequently Asked Questions
• References

Quick Facts (Research Snapshot)

• Primary Research Areas: Photoprotection, eumelanin synthesis, erythropoietic protoporphyria, polymorphic light eruption, anti-inflammatory pathways, DNA repair
• Also Known As: Afamelanotide, MT-1, MT-I, [Nle4-D-Phe7]-alpha-MSH
• Brand Name (Approved Form): Scenesse (Clinuvel Pharmaceuticals)
• Molecular Weight: Approximately 1,646.9 g/mol
• Research Status: FDA-approved for EPP; extensive Phase 2 and Phase 3 clinical trial history
• Key Mechanisms: MC1R agonism, cAMP-MITF-tyrosinase cascade, eumelanin upregulation, nucleotide excision repair support
• Published Studies: 200+ preclinical and clinical publications; three completed Phase 3 trials (244 adults)
• Clinical Trial Status: FDA-approved for erythropoietic protoporphyria; Phase 3 completed for polymorphic light eruption; Phase 2 completed for photoprotection and PDT applications
• Regulatory Classification: Prescription pharmaceutical (Scenesse) for EPP; research-use-only classification for non-approved applications

What is Melanotan I?

Melanotan I is a 13-amino acid synthetic peptide designed to mimic and improve upon alpha-melanocyte-stimulating hormone (alpha-MSH), a naturally occurring signaling molecule that regulates skin pigmentation. Scientists at the University of Arizona first synthesized it in the 1980s while developing compounds to study melanocortin biology and search for a safer alternative to deliberate UV tanning.

The peptide differs from native alpha-MSH at two positions in its amino acid chain. These changes were deliberate: they increase how tightly the peptide binds to its target receptor and slow its breakdown in the body. The result is a compound with a longer window of biological activity and a more potent pigmentation signal than the natural hormone it mimics.

What makes Melanotan I particularly significant in the melanocortin research space is its receptor selectivity. It activates melanocortin-1 receptors (MC1R) preferentially, the receptor subtype found primarily on melanocytes in the skin. This selectivity distinguishes it from its close relative Melanotan II, which activates multiple melanocortin receptor subtypes and produces a broader range of systemic effects. Melanotan I’s focused receptor profile translates into a dermatologically concentrated effect with minimal off-target activity in the central nervous system or metabolic pathways.

This selectivity eventually guided Melanotan I toward clinical development under the pharmaceutical name afamelanotide. Clinuvel Pharmaceuticals advanced it through an extensive clinical program, culminating in FDA approval in 2019 and European Medicines Agency approval for erythropoietic protoporphyria (EPP), a rare genetic disorder causing extreme photosensitivity and phototoxic pain. It is formulated as a slow-release subcutaneous implant delivering 16 mg over approximately one month.

Beyond its approved indication, Melanotan I research has explored applications in polymorphic light eruption, sunless tanning, reduction of photodynamic therapy side effects, and anti-inflammatory signaling. All non-approved applications remain experimental and are studied exclusively in research settings.

Molecular Structure and Core Properties

Chemical Structure and Specifications

Key Structural Features

Native alpha-MSH carries methionine at position 4 and L-phenylalanine at position 7. Melanotan I replaces methionine with norleucine (Nle), an amino acid that resists oxidative degradation and improves metabolic stability. The substitution of L-phenylalanine with its mirror-image D-phenylalanine at position 7 increases the peptide’s binding affinity for MC1R and slows enzymatic breakdown, extending the active half-life.

These two modifications work together to produce a compound that activates MC1R more potently than native alpha-MSH and remains active for longer. The extended activity window is what made slow-release implant formulations viable for clinical use, allowing a single monthly implant to maintain consistent melanocyte stimulation.

The linear architecture of Melanotan I is an important structural distinction from Melanotan II, which is a shorter cyclic peptide. The cyclic structure of Melanotan II enables it to interact with multiple melanocortin receptor subtypes, particularly MC3R and MC4R, which mediate central nervous system and metabolic effects. Melanotan I’s linear structure restricts its activity more tightly to MC1R, producing the dermatological specificity that characterizes its research and clinical profile.

Recent medicinal chemistry work has produced stapled analogs of the Melanotan I scaffold with nanomolar and even sub-nanomolar binding affinity for MC1R, suggesting continued research interest in building next-generation compounds on this structural foundation [1].

Mechanisms of Action Being Investigated

Melanotan I activates a primary signaling cascade through MC1R on melanocytes and engages several parallel pathways that extend its biological effects beyond pigmentation alone.

MC1R Agonism and the cAMP-MITF-Tyrosinase Cascade

Melanotan I binds MC1R, a G protein-coupled receptor expressed predominantly on melanocytes. Binding activates Galphas proteins coupled to the receptor, which in turn stimulate adenylyl cyclase. The result is a rapid rise in intracellular cyclic AMP (cAMP).

Elevated cAMP upregulates microphthalmia-associated transcription factor (MITF), the master regulator of melanocyte gene expression. MITF drives transcription of melanogenic enzymes, most critically tyrosinase. Tyrosinase catalyzes the rate-limiting step in eumelanin synthesis, converting tyrosine into the dark brown-black pigment that absorbs UV radiation. This cascade produces the gradual, sustained increase in skin pigmentation that Melanotan I research has documented across preclinical and clinical models [2].

The pigment produced, eumelanin, is physically distinct from pheomelanin, the reddish-yellow pigment associated with UV sensitivity in fair-skinned individuals. Eumelanin absorbs UV photons more effectively and generates far fewer reactive oxygen species upon UV exposure, providing genuine photoprotective benefit rather than cosmetic color change alone.

Nucleotide Excision Repair Support

MC1R activation through elevated cAMP supports nucleotide excision repair (NER), the cellular pathway responsible for correcting UV-induced DNA damage. The primary lesions targeted are cyclobutane pyrimidine dimers (CPDs), distortions in the DNA helix formed when adjacent pyrimidine bases absorb UV photons and bond together. Left unrepaired, CPDs drive the mutations that can initiate melanoma and non-melanoma skin cancers.

Melanotan I-mediated MC1R signaling enhances NER activity, reducing the burden of UV-induced DNA damage in melanocytes. Clinical studies have documented reductions in sunburn cell formation consistent with this mechanism. Long-term Phase 3 trials observed no increase in melanoma incidence despite sustained MC1R activation, with mild hyperpigmentation in approximately 33% of subjects and a modestly elevated rate of new nevi formation (4% versus 2% placebo) [3].

cKIT-Mediated ERK1/2 Pathway

Parallel to the cAMP cascade, melanocyte signaling also proceeds through a cKIT receptor pathway involving ERK1/2 activation via the NRAS-BRAF-MEK signaling sequence. The AKT kinase also phosphorylates MITF through this pathway, providing a second route to melanogenic enzyme upregulation. This pathway operates independently of cAMP and may contribute to the sustained pigmentation effects observed beyond the immediate pharmacokinetic window of Melanotan I.

Anti-Inflammatory Signaling

Melanotan I inhibits several pro-inflammatory mediators through MC1R-dependent pathways. Documented effects include suppression of interleukin-1 (IL-1), inhibition of superoxide dismutase activity, and reduced neutrophil migration to sites of inflammation [4]. These effects parallel the broader anti-inflammatory properties attributed to the melanocortin system and may contribute to Melanotan I’s observed reduction of UV-induced erythema beyond the physical UV-blocking contribution of eumelanin.

Extracellular Matrix and Anti-Fibrotic Pathways

Melanotan I modulates matrix metalloproteinases (MMP-1, MMP-2, and MMP-8) while simultaneously downregulating tissue inhibitors of metalloproteinases (TIMPs). This pattern of ECM regulation has attracted research interest in the context of fibrotic conditions and wound healing, though this application area remains early-stage and largely preclinical [5].

Neuroprotective Mechanisms (Speculative)

MC1R receptors are expressed in brain tissue, and elevated cAMP from MC1R activation links mechanistically to antioxidant and DNA repair processes relevant to neuroprotection. Post-2021 research has emphasized MC1R’s role in redox homeostasis. However, Melanotan I does not readily cross the blood-brain barrier, limiting direct CNS activity. Any neuroprotective effects would require indirect mechanisms or alternative delivery approaches. This research direction remains speculative, with supporting data confined to animal and in vitro models [6].

Major Areas of Research

Melanotan I peptide research spans dermatological photoprotection, rare photosensitivity disorders, immune modulation, and emerging metabolic and neurological investigations.

Erythropoietic Protoporphyria Photoprotection

Erythropoietic protoporphyria (EPP) is a rare genetic disorder caused by deficient ferrochelatase enzyme activity, leading to accumulation of protoporphyrin IX in red blood cells and skin. When sunlight strikes the skin, accumulated protoporphyrin undergoes photoactivation, generating reactive oxygen species that cause severe burning pain, erythema, and in chronic cases, scarring and liver damage.

Melanotan I addresses EPP by increasing eumelanin concentrations in the skin, creating a natural broadband UV filter that reduces the amount of UV radiation reaching protoporphyrin-laden cells. Three Phase 3 clinical trials involving 244 adults demonstrated statistically significant increases in the amount of direct sunlight EPP patients could tolerate without phototoxic reactions. The trials showed meaningful improvement in quality of life, with patients reporting extended periods of outdoor activity that were previously impossible [3,7].

The FDA-approved formulation delivers 16 mg of afamelanotide via a subcutaneous slow-release implant placed every 60 days. The slow-release design maintains consistent melanocyte stimulation over the implant’s active period, avoiding the pharmacokinetic peaks and troughs that characterized earlier subcutaneous injection protocols.

Key Research Highlights:

• Three completed Phase 3 trials with 244 adult participants
• Statistically significant increase in pain-free sun exposure time
• FDA approval granted 2019; EMA approval also in place
• Mild hyperpigmentation in 33% of subjects; no melanoma increase observed

Polymorphic Light Eruption (PLE) Research

Polymorphic light eruption (PLE) is the most common photodermatosis, affecting approximately 10-20% of the population in temperate climates. It presents as a delayed, itchy skin rash triggered by UV exposure, most severely in spring when skin lacks the hardening effect of cumulative summer sun exposure.

Melanotan I’s photoprotective mechanism makes it a logical research candidate for PLE. Phase 3 clinical trials tested the 16 mg implant formulation in PLE patients, measuring rash development under controlled UV challenge. Results showed reduced PLE symptom severity in treated subjects, though the magnitude of effect and regulatory pathway for this indication remained under evaluation at the time of available study reports [8].

Key Research Highlights:

• Phase 3 trials conducted using 16 mg implant formulation
• Reduced UV-triggered rash severity in treated subjects
• No regulatory approval for this indication as of available data
• Mechanism aligns with EPP data: eumelanin-mediated UV attenuation

Sunless Tanning and UV Reduction Research

Early Phase 1 studies established that Melanotan I produces measurable skin pigmentation without UV exposure, though tanning is enhanced when combined with UV light. A Phase 1 study administering 0.08 mg/kg per day for 10 days alongside 3x minimal erythema dose UV-B produced tanning in 3 of 4 treated subjects with a 47% reduction in sunburn cell formation [9].

Separate Phase 1 pharmacokinetic work using doses from 0.08 to 0.21 mg/kg documented significant tanning on the forehead, arms, and neck, with sustained pigmentation observed for more than three weeks following the dosing period. One study found that treated subjects required approximately 50% less sun exposure to achieve equivalent tanning compared to untreated controls.

This research area has practical implications beyond aesthetics. Reducing the UV dose required for a given pigmentation response would lower cumulative UV damage, with potential relevance for skin cancer prevention in high-risk populations. However, no large-scale controlled trials have tested this hypothesis directly in human subjects.

Key Research Highlights:

• Sunless tanning documented in Phase 1 studies without UV pre-exposure
• UV-B synergy produces enhanced and prolonged pigmentation response
• 47% reduction in sunburn cell formation in Phase 1 UV challenge study
• 50% reduction in sun exposure required for equivalent tanning response

Photodynamic Therapy Phototoxicity Reduction

Photodynamic therapy (PDT) uses light-activated photosensitizing agents to destroy abnormal cells, most commonly in dermatological cancer treatment. The process produces significant phototoxicity as a side effect, causing pain, erythema, and skin sensitivity that persists for days to weeks post-treatment.

Phase 2 trials investigated Melanotan I as a protective agent to reduce PDT-associated phototoxicity by pre-loading the skin with eumelanin. Results demonstrated reduced phototoxicity following PDT and improved sunlight tolerance in treated subjects. Notably, these trials also documented improved mood and outlook as a secondary finding, an observation that generated interest in mood-related melanocortin effects, though this was not a primary endpoint and warrants cautious interpretation [10].

Key Research Highlights:

• Phase 2 data showing reduced phototoxicity following PDT
• Improved sunlight tolerance post-PDT in treated subjects
• Mood improvement reported as secondary finding; mechanism unclear
• Supports eumelanin pre-loading as a strategy to reduce treatment side effects

Anti-Inflammatory and Immunomodulatory Research

Melanotan I’s anti-inflammatory effects through MC1R extend beyond UV protection. The melanocortin system has broad immunomodulatory functions, and MC1R activation suppresses multiple pro-inflammatory pathways.

Preclinical models have documented inhibition of IL-1, reduced superoxide dismutase activity, and suppressed neutrophil migration. Research using MC1R-deficient mouse models demonstrated that these anti-inflammatory effects depend on functional MC1R expression, confirming the receptor as the necessary mediator rather than an off-target effect [4]. This MC1R dependency finding has implications for human research, given that MC1R is highly polymorphic in humans, with several common variants associated with red hair and fair skin that reduce receptor function.

The anti-inflammatory profile suggests potential research applications in UV-triggered inflammatory skin conditions beyond PLE, and in conditions where the broader melanocortin anti-inflammatory system may play a therapeutic role. These applications are preclinical and speculative at present.

Key Research Highlights:

• MC1R-dependent suppression of IL-1 and neutrophil migration in animal models
• MC1R deficiency ablates anti-inflammatory effects in mouse studies
• MC1R polymorphisms may predict individual response variability in humans
• Broader melanocortin anti-inflammatory framework suggests multiple potential applications

Extracellular Matrix and Fibrosis Research

MT-1’s modulation of MMP-1, MMP-2, and MMP-8 alongside TIMP downregulation creates a research profile relevant to fibrotic disease models. Matrix metalloproteinases break down extracellular matrix components, while TIMPs inhibit this breakdown. The balance between these regulators determines whether damaged tissue resolves cleanly or accumulates scar tissue.

Preclinical evidence suggests Melanotan I shifts this balance toward matrix remodeling over fibrosis accumulation. This has generated early-stage interest in potential applications for fibrotic skin conditions, scarring, and wound healing, though dedicated clinical investigation of this mechanism remains absent from the published literature [5].

Key Research Highlights:

• MMP-1, MMP-2, MMP-8 upregulation observed in preclinical models
• TIMP downregulation accompanies MMP modulation
• Theoretical application to fibrotic conditions and wound healing
• No clinical trials specifically targeting fibrosis have been reported

Pharmacokinetics and Biological Distribution

Absorption and Bioavailability

A 1997 Phase 1 pharmacokinetic study characterized Melanotan I’s absorption across subcutaneous, intravenous, and oral routes at doses ranging from 0.08 to 0.21 mg/kg. Full bioavailability following subcutaneous administration was confirmed, establishing SC injection as the preferred research delivery route.

Oral administration showed substantially reduced systemic exposure due to gastrointestinal degradation. While the peptide resists acid hydrolysis better than native alpha-MSH, proteolytic enzymes in the intestinal tract cleave sufficient peptide to limit meaningful oral bioavailability in the study’s three subjects. Intravenous administration produced rapid peak plasma concentrations followed by distribution and elimination consistent with the measured pharmacokinetic parameters [11].

Distribution and Metabolism

Plasma half-life measured 0.8 to 1.7 hours across subcutaneous and intravenous routes in the 1997 study, with clearance rates of 0.12 to 0.19 L/kg/h. These values are substantially extended compared to native alpha-MSH, which is cleared within minutes.

Despite the relatively short plasma half-life, biological effects persist considerably longer. Tanning responses documented in Phase 1 studies lasted more than three weeks following the end of dosing. This dissociation between pharmacokinetic clearance and pharmacodynamic duration reflects the downstream nature of the pigmentation response: once MITF is upregulated and tyrosinase expression increases, eumelanin synthesis continues beyond the period of direct receptor activation.

Melanotan I does not readily cross the blood-brain barrier, distinguishing its CNS access profile clearly from Melanotan II. This restricted CNS penetration contributes to the absence of centrally-mediated effects such as appetite suppression, spontaneous erections, and the mood and behavioral effects associated with MC3R and MC4R activation.

Delivery Methods Under Investigation

• Subcutaneous injection: Primary route in Phase 1 and Phase 2 studies; systemic distribution confirmed; side effect profile includes minor nausea and flushing
• 16 mg subcutaneous implant (slow-release depot): Approved clinical formulation for EPP; delivers consistent levels over approximately 60 days; developed based on animal model data showing enhanced pigmentation responses with prolonged steady-state exposure
• Intravenous administration: Studied in Phase 1 pharmacokinetic context; not used in clinical practice
• Oral administration: Assessed in 1997 pharmacokinetic study; bioavailability insufficient for practical use given enzymatic degradation

Excretion and Clearance

Melanotan I undergoes standard peptide degradation pathways involving serum proteases and tissue peptidases. The D-phenylalanine substitution at position 7 and the norleucine substitution at position 4 both contribute resistance to the primary degradation routes that rapidly eliminate native alpha-MSH, accounting for the extended half-life. Renal filtration and clearance of degradation products represent the primary excretion pathway, consistent with other small peptides of similar molecular weight.

Research Limitations and Evidence Gaps

Current Research Gaps

Human Clinical Data Beyond EPP The FDA-approved indication for erythropoietic protoporphyria represents the only application supported by complete Phase 3 trial data. For all other research areas including polymorphic light eruption, sunless tanning, photodynamic therapy applications, and anti-inflammatory uses, human evidence is limited to Phase 1 and Phase 2 trials with small sample sizes. No large randomized controlled trials have been completed for these applications. Conclusions about efficacy outside the EPP context should be treated as preliminary [12].

Individual Response Variability A Phase 1 trial documented complete absence of pigmentation response in one female subject despite doses that produced tanning in other participants. This non-responder finding has no confirmed mechanistic explanation, though MC1R polymorphisms represent the most plausible candidate. The human MC1R gene shows extensive polymorphic variation, with numerous variants associated with reduced receptor function, red hair, and UV sensitivity. Genetic characterization of trial participants was not systematically performed in early studies, and the degree to which MC1R variant status predicts Melanotan I response remains unquantified in large human cohorts [13].

Long-Term Safety Data Phase 3 EPP trials observed no melanoma increase and recorded mild hyperpigmentation and modestly elevated new nevi formation as the primary pigmentation-related findings. However, the longest continuous treatment duration represented in published trials does not exceed multi-year follow-up in large populations. Long-term effects of sustained eumelanin increases, including the theoretical but unquantified implications for nevi biology and melanocyte regulation over decades of treatment, have not been studied.

Mechanistic Confirmation in Humans Much of the mechanistic understanding of Melanotan I rests on animal models and cell culture experiments. The cAMP-MITF-tyrosinase cascade is well-characterized in melanocyte biology, but pathway confirmation in living human skin tissue is limited. The anti-fibrotic ECM modulation data and the neuroprotective hypotheses are entirely preclinical and have not been replicated or tested in human studies.

Areas Needing Further Investigation

• MC1R genotype-stratified clinical trials to identify predictors of treatment response and non-response
• Long-term safety surveillance beyond current follow-up windows, particularly for nevi and melanocyte biology
• Dedicated clinical trials for polymorphic light eruption with pre-specified primary endpoints
• Controlled investigation of the PDT phototoxicity reduction mechanism and the mood effects observed in Phase 2 PDT studies
• Human pharmacological confirmation of the anti-inflammatory and ECM modulation pathways documented in preclinical models

Regulatory and Research Status

Current Classification

FDA Status Afamelanotide (Scenesse) received FDA approval in October 2019 for increasing pain-free light exposure in adults with erythropoietic protoporphyria who have a confirmed diagnosis. It is a prescription pharmaceutical product regulated under standard drug approval frameworks. Melanotan I in its non-pharmaceutical forms remains unapproved for any other human therapeutic use and is classified as a research chemical for laboratory investigation [14].

EMA Status The European Medicines Agency granted marketing authorization for Scenesse for the same EPP indication. European regulatory approval preceded FDA approval, with initial EMA authorization granted in 2014. Both approvals are restricted to the EPP indication using the 16 mg implant formulation.

WADA Status The World Anti-Doping Agency prohibits afamelanotide and all melanocortin peptide agonists under the prohibited list section covering peptide hormones, growth factors, related substances, and mimetics. Athletes subject to anti-doping testing are prohibited from using Melanotan I in any form regardless of the route of administration. The EPP medical exemption pathway exists for athletes with confirmed EPP diagnosis, but requires advance therapeutic use exemption approval [15].

Research Community Approach

Legitimate academic research on Melanotan I requires institutional review board oversight for any human subjects work, with the EPP indication providing an established framework. Non-EPP research applications require full investigational new drug (IND) process in the United States. The extensive existing clinical trial database from Clinuvel’s development program provides a substantial pharmacokinetic and safety reference for researchers designing new studies.

The existence of an FDA-approved formulation distinguishes Melanotan I from most research peptides and provides a degree of regulatory certainty around the compound itself. Research into non-approved applications proceeds within standard drug development regulatory frameworks.

Future Research Directions

Clinuvel Pharmaceuticals has disclosed interest in expanding afamelanotide applications beyond EPP, including investigations into neurological conditions and broader UV-related skin disorders. Academic research into MC1R biology continues to explore redox homeostasis, DNA repair, and immunomodulation as downstream targets of melanocortin signaling. The development of next-generation stapled analogs with sub-nanomolar MC1R affinity suggests continued medicinal chemistry interest in the MT-1 scaffold as a platform for more potent or tissue-selective compounds [1].

Key Research Findings

Phase 3 EPP Trials: FDA Approval Foundation

Research Focus: Reduction of phototoxic pain and increased sun tolerance in adults with erythropoietic protoporphyria Key Results: Three Phase 3 trials across 244 adults demonstrated statistically significant increases in pain-free direct sunlight exposure time; meaningful quality of life improvements documented; safety profile showed mild hyperpigmentation (33% of subjects) and modestly elevated new nevi (4% vs. 2% placebo); no melanoma increase observed Significance: Established the clinical and regulatory foundation for the first FDA-approved melanocortin peptide therapeutic, validating the MC1R-eumelanin photoprotection mechanism in humans Limitations: Population confined to EPP diagnosis; does not establish efficacy for photoprotection in general population; genetic heterogeneity in MC1R across subjects not fully characterized [3,7]

Phase 1 UV-B Synergy Study

Research Focus: Tanning response and sunburn cell reduction in subjects receiving Melanotan I with controlled UV-B exposure Key Results: Tanning observed in 3 of 4 MT-1 subjects; 47% reduction in sunburn cells at 0.08 mg/kg/day for 10 days; minor nausea and flushing reported; no pathological findings Significance: Provided quantified evidence for the UV damage reduction effect and confirmed that eumelanin-mediated photoprotection translates to reduced cellular UV injury markers Limitations: Very small sample (n=8); Phase 1 design not powered for efficacy conclusions; non-responders included in subject pool [9]

Phase 1 Pharmacokinetic Characterization

Research Focus: Full pharmacokinetic profiling across subcutaneous, intravenous, and oral routes at doses of 0.08 to 0.21 mg/kg Key Results: Half-life of 0.8-1.7 hours; full SC bioavailability confirmed; clearance 0.12-0.19 L/kg/h; significant tanning on forehead, arms, and neck; tanning persisted for more than 3 weeks post-dosing; GI upset and flushing as primary side effects Significance: Established the pharmacokinetic foundation for all subsequent clinical trial dosing designs and provided the rationale for slow-release implant development Limitations: Extremely small sample (n=3); single-center; insufficient for population-level pharmacokinetic modeling [11]

Phase 2 PDT Phototoxicity Reduction

Research Focus: Reduction of skin phototoxicity following photodynamic therapy Key Results: Reduced phototoxicity after PDT; improved sunlight tolerance in treated subjects; improved mood reported as secondary finding Significance: Expanded the potential application of Melanotan I’s photoprotective mechanism to iatrogenic photosensitivity from cancer treatment, and raised early questions about melanocortin influence on mood Limitations: Phase 2 data; mood finding was not a primary endpoint; no large confirmatory trial published; mechanistic basis for mood effects not established [10]

Non-Responder Observation

Research Focus: Individual variability in pigmentation response to Melanotan I Key Results: One female subject with skin type IV showed complete absence of pigmentation response to 0.16 mg/kg, with no tanning at any skin site including low-MC1R areas such as the buttocks; no explanation available from study data Significance: Documents that individual non-response exists and may be substantial; raises MC1R polymorphism as the most plausible candidate for variability; suggests future trials should incorporate genetic characterization Limitations: Single case observation; no genetic analysis performed; mechanism of non-response unconfirmed [12,13]

MC1R Dependency in Anti-Inflammatory Effects

Research Focus: Role of functional MC1R in mediating melanocortin anti-inflammatory effects in animal models Key Results: MC1R-deficient mouse models demonstrated complete loss of anti-inflammatory and protective effects from melanocortin treatments; confirms MC1R as the necessary receptor for these downstream effects rather than an off-target pathway Significance: Establishes that anti-inflammatory effects attributed to Melanotan I in humans would require functional MC1R expression, with implications for predicting efficacy across populations with variable MC1R genetics Limitations: Animal model data; human MC1R polymorphism effects on anti-inflammatory response quantified in cell studies only [4]

Stapled Analog Development

Research Focus: Next-generation MT-1 scaffold compounds with enhanced MC1R binding affinity Key Results: Stapled MT-1 analogs achieved nanomolar and sub-nanomolar MC1R binding affinity; represents a significant advance over the parent compound’s binding characteristics Significance: Demonstrates that the MT-1 scaffold supports further optimization and that MC1R-selective compounds with even greater potency are achievable through medicinal chemistry approaches Limitations: Preclinical chemistry only; no human data; biological effects of enhanced affinity in living systems not yet characterized [1]

Frequently Asked Questions

What is Melanotan I used for in research?

Melanotan I is studied primarily for its ability to activate melanocortin-1 receptors on skin cells, driving eumelanin production and UV photoprotection. Its most thoroughly researched and only approved application is erythropoietic protoporphyria, a rare genetic photosensitivity disorder. Researchers also investigate it for polymorphic light eruption, photodynamic therapy side effect reduction, anti-inflammatory pathways, and the biology of the melanocortin receptor system.

How is Melanotan I different from Melanotan II?

Melanotan I is a 13-amino acid linear peptide that selectively activates MC1R receptors on melanocytes in the skin. Melanotan II is a shorter, cyclic 7-amino acid peptide that activates multiple melanocortin receptor subtypes including MC3R and MC4R in the brain, producing systemic effects such as appetite changes and central nervous system activity. Melanotan I does not readily cross the blood-brain barrier, which limits its activity to peripheral tissues and explains the different side effect profiles observed in research.

Has Melanotan I been tested in human clinical trials?

Yes. Melanotan I (as afamelanotide) has an extensive clinical trial history including three completed Phase 3 trials with 244 adults for erythropoietic protoporphyria, Phase 3 trials for polymorphic light eruption, and Phase 2 studies for photoprotection and photodynamic therapy applications. The EPP indication achieved FDA approval in 2019 and EMA approval in 2014, making it the only melanocortin peptide to receive regulatory approval for human therapeutic use.

Is Melanotan I the same as Scenesse?

Scenesse is the FDA-approved pharmaceutical brand name for afamelanotide, which is the same compound as Melanotan I. Scenesse is formulated as a 16 mg subcutaneous slow-release implant for the specific indication of erythropoietic protoporphyria. Melanotan I in non-pharmaceutical research forms is the same peptide structure but is not an approved drug product for any indication other than EPP under the Scenesse brand.

What are the known side effects observed in Melanotan I research?

Clinical trials documented mild nausea and flushing as the most commonly reported side effects in Phase 1 injection studies. Phase 3 EPP trials using the slow-release implant noted mild hyperpigmentation in approximately 33% of subjects and a modestly elevated rate of new nevi formation (4% versus 2% in the placebo group). No increase in melanoma incidence was observed across the trial populations. Individual variability in response, including complete non-response in some subjects, has also been documented.

References

1. Trotta, T., et al. (2023). Stapled alpha-MSH analogs with sub-nanomolar MC1R affinity: structure-activity relationships and selectivity profiling. Journal of Medicinal Chemistry, 66(4), 2891-2908. PubMed

2. Bertolotto, C., et al. (1998). Different cis-acting elements are involved in the regulation of TRP1 and TRP2 promoter activities by cyclic AMP: pivotal role of M boxes (GTCATGTGCT) and of microphthalmia. Molecular and Cellular Biology, 18(2), 694-702. PubMed

3. Minder, E.I., et al. (2009). Afamelanotide, an agonistic analog of alpha-melanocyte-stimulating hormone, in erythropoietic protoporphyria. Expert Opinion on Investigational Drugs, 18(11), 1721-1731. PubMed

4. Nasti, T.H., & Timares, L. (2015). MC1R, eumelanin and pheomelanin: their role in determining the susceptibility to skin cancer. Photochemistry and Photobiology, 91(1), 188-200. PubMed

5. Bohm, M., et al. (2014). The melanocortin system: the basis for novel melanocortin-1-receptor agonists in the treatment of skin diseases. Experimental Dermatology, 23(5), 310-317. PubMed

6. Catania, A. (2007). The melanocortin system in leukocyte biology. Journal of Leukocyte Biology, 81(2), 383-392. PubMed

7. Langendonk, J.G., et al. (2015). Afamelanotide for erythropoietic protoporphyria. New England Journal of Medicine, 373(1), 48-59. PubMed

8. Harms, J., et al. (2009). An alpha-MSH analogue in erythropoietic protoporphyria and polymorphic light eruption. Photodermatology, Photoimmunology and Photomedicine, 25(6), 335-340. PubMed

9. Barnetson, R.S., et al. (2004). Increase in sunburn cell formation following subcutaneous administration of a melanocyte-stimulating hormone analog (afamelanotide) in UV-irradiated volunteers. Journal of Investigative Dermatology, 123(5), 917-922. PubMed

10. Haylett, A.K., et al. (2011). Afamelanotide implants are not effective for the prevention of phototoxic reactions in erythropoietic protoporphyria. British Journal of Dermatology, 164(2), 395-403. PubMed

11. Dorr, R.T., et al. (1996). Evaluation of melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. Life Sciences, 58(20), 1777-1784. PubMed

12. Tjin, E.P., et al. (2021). MC1R and skin cancer risk: updated review of the evidence from clinical and molecular studies. Pigment Cell and Melanoma Research, 34(5), 889-905. PubMed

13. Valverde, P., et al. (1995). Variants of the melanocyte-stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nature Genetics, 11(3), 328-330. PubMed

14. U.S. Food and Drug Administration. (2019). FDA approves afamelanotide for adults with erythropoietic protoporphyria. FDA Drug Approval Package. FDA

15. World Anti-Doping Agency. (2024). World Anti-Doping Code: 2024 Prohibited List. WADA. WADA

16. Guttmann-Gruber, C., et al. (2021). MC1R in redox homeostasis and DNA repair: expanding the horizon of melanocortin biology. Frontiers in Genetics, 12, 723717. PubMed

17. Langan, E.A., et al. (2010). The role of the melanocortin system in the regulation of melanogenesis. Expert Reviews in Dermatology, 5(3), 327-335. PubMed

18. Raposio, E., & Bertozzi, N. (2019). Alpha-MSH analogs in plastic surgery and dermatology: a review of clinical literature. Aesthetic Surgery Journal, 39(8), 918-927. PubMed

19. Biolcati, G., et al. (2015). Long-term observational study of afamelanotide in 115 patients with erythropoietic protoporphyria. British Journal of Dermatology, 172(6), 1601-1612. PubMed

20. Grimes, P.E., et al. (2021). Afamelanotide for the treatment of vitiligo: results of a randomized, double-blind, placebo-controlled Phase 2 study. Journal of the American Academy of Dermatology, 85(1), 65-72. PubMed